BLU-667 Shows Promise for Advanced Solid Tumors With RET Alterations

BLU-667, a next-generation tyrosine kinase inhibitor, appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies, according to phase I study findings presented at the AACR Annual Meeting 2018, held April 14 to 18 in Chicago, Illinois.

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *